A method was developed for the determination of nucleotides in infant formula milk powder by ion chromatography (IC). The separation was performed on an IonPac AS16 column with KOH solution as the mobile phase at a flow rate of 1.0 mL/min and 25 degrees C. The detection wavelength was set at 260 nm and the sample injection volume was 25 microL. There were good linear relationships between the mass concentrations and the peak areas of cytidine monophosphate (CMP), adenosine monophosphate (AMP), uridine monophosphate (UMP), inosine monophosphate (IMP) and guanosine monophosphate (GMP) in the ranges of 0.09-50, 0.06-50, 0.06-50, 0.09-50, 0.06-50 mg/L, respectively. The limits of detection (S/N = 3) of CMP, AMP, UMP, IMP and GMP were 0.03, 0.02, 0.02, 0.03 and 0.02 mg/L, respectively. The method has been applied for the determination of the five nucleotides in infant formula milk powder with the recoveries of 92.5%-102.4%. This method is rapid, simple and suitable for the determination of real samples.

01 May 2009·Se pu = Chinese journal of chromatography

[Simultaneous determination of hexafluorophosphate and other trace impurity anions in ionic liquids by ion chromatography].

Article

Author: Pan, Guangwen ; Ye, Mingli ; Hu, Zhongyang

A method was developed for the simultaneous determination of hexafluorophosphate and other trace impurity anions in ionic liquids by ion chromatography (IC). The sample was diluted with 70% (v/v) acetonitrile, filtrated by 0.22 microm nylon filter membrane, and then analyzed by IC. The analytical column was Dionex IonPac AS22 (250 mm x 4 mm), carbonate-acetonitrile (70:30, v/v) was used as the eluent at a flow rate of 1.0 mL/min. The detection was performed by a Dionex DS6 conductivity detector. The quantitive analysis of external standard calibration curves was used. The linear ranges of the method for F(-), Cl(-), Br(-) and PF6(-) were 0.5 - 50 microg/L (r = 0.9999), 10 - 200 microg/L (r = 0.9998), 10 - 200 microg/L (r = 0.9999) and 0.9 - 45 mg/L (r = 0.9998), respectively. The average recoveries were 94.5% - 100.5% with the relative standard deviations of 0.63% - 1.03%. The detection limits (S/N = 3) were 0.5 microg/L, 2.0 microg/L, 5.0 microg/L and 0.9 mg/L for F(-), Cl(-), Br(-) and PF6(-), respectively. The method has been applied to determine hexafluorophosphate and other trace impurity anions in ionic liquids with satisfactory results.

Huanjing Huaxue

Analysis 7 surfactants using Dionex Surfactant column and CAD

Author: Anonymous

100 Deals associated with Dionex China Ltd.

100 Translational Medicine associated with Dionex China Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 13 Nov 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Dionex China Ltd.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 13 Nov 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing